Quectel response to FCC about IoT module security
7.9.2023 16:03:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today commented on the recent letter and response being published by the FCC and the Select Committee of the US Congress questioning if Quectel’s IoT modules represent a potential security risk.
“We welcome the opportunity to work with the FCC and other U.S. government entities to demonstrate our compliance and best practice device security approach, says Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We are committed to contributing to the advancement of a smarter world by delivering best-in-class and secure products. This commitment is evidenced by our extensive device OEM customer base and our constant focus on providing our customers with the best and most secure modules in the industry.”
The Select Committee to the US Congress’ letter to the FCC had several misconceptions about how Quectel modules work. Quectel’s clarification regarding the statements made in the letter is as follows.
Committee letter: “Connectivity modules are typically controlled remotely and are the necessary link between the device and the internet.”
Quectel’s U.S. customers or their customers’ third-party suppliers/service providers handle device and data management exclusively. Firmware updates are managed and controlled by the device original equipment manufacturer (OEM), not Quectel.
Committee letter: “Serving as the link between the device and the internet, these modules have the capacity both to brick the device and to access the data flowing from the device to the web server that runs each device”
The control of Quectel modules resides with the microcontroller unit (MCU) or central processing unit (CPU) embedded within the customer's device. Quectel itself does not possess any control; instead, this authority rests solely with the OEM – the entity responsible for developing the device. Remote management of the device is achievable solely through the OEM's device management platform. A notable instance of this, referred to in the letter, is the widely covered case involving John Deere agricultural equipment, where just the OEM typically can disable the equipment by accessing and shutting down its own MCU’s controlling the machine.
Committee letter: “As a result, if the CCP can control the module, it may be able to effectively exfiltrate data or shut down the IoT device.”
Once Quectel modules leave the factory and are delivered to its customers, Quectel customers own the data, and Quectel has no access to any of the data collected. The ownership, control, storage, and modification of the data generated by IoT devices within the market firmly rest with the OEM device makers and its customers. Even in the rare cases outside of the U.S. where Quectel resells the connectivity service of a wireless carrier, Quectel does not have access to the device data.
Committee letter: “This raises particularly grave concerns in the context of critical infrastructure and any type of sensitive data.”
Applications that require high security, such as critical infrastructure, typically use private access point names (APNs) and other methods which strictly control and monitor network access. This can be used to control and monitor any data flowing to and from the device. Critical infrastructure is meticulously fashioned with a multi-tiered security approach defined and implemented solely by the device OEM, not Quectel.
The cellular industry is heavily regulated and requires intensive testing and accreditation. Carrier and regulatory certifications are executed by trusted third-party labs and carrier labs, assuring that the module complies with strict technical requirements. The Quectel modules have obtained certifications from the FCC, PCS Type Certification Review Board (PTCRB) and major carriers throughout the world, which underlines Quectel’s commitment to meeting rigorous industry standards.
In addition to cellular modules, Quectel also provides Wi-Fi, Bluetooth and GNSS modules and antennas. As a GSMA member, Quectel and its carrier partners comply with all cellular industry regulations and applicable standards to ensure that end customer data is securely transmitted between customer device and mobile network operator. Quectel does not have access to ANY of the device data.
Quectel is committed to delivering high-quality, best-in-class, secure modules and go above and beyond industry standard practices by conducting independent third-party cyber security audits. More recently Quectel also retained the security firm Finite State, which is auditing and penetration testing the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management. Quectel is also participating in the formulation of new industry security certification standards, such as the CTIA Cybersecurity Certification Working Group and pursuing additional cyber security certifications from various U.S. entities as new standards are formulated and adopted.
Qualcomm manufactures the chipsets and software platforms that are at the core of the Quectel modules. “Our Qualcomm partnership underlines the importance we place on working with well-trusted and secure partners from across the ecosystem to deliver high-quality solutions globally,” Mr. Muhrer continues. “Quectel's impact on the global IoT industry is profound. We supplied millions of cellular modules to support the distribution of Covid-19 vaccines for leading U.S. and global organizations including Pfizer, Johnson & Johnson, and other leading suppliers of vaccines. This underscores our commitment to playing a pivotal role in critical global initiatives.”
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X (formerly known as Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907525548/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
